BeiGene Ltd. (BGNE)
| Market Cap | 33.43B |
| Revenue (ttm) | 947.04M |
| Net Income (ttm) | -1.31B |
| Shares Out | 93.33M |
| EPS (ttm) | -14.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,935 |
| Open | 358.55 |
| Previous Close | 355.46 |
| Day's Range | 351.05 - 359.21 |
| 52-Week Range | 219.20 - 426.56 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 424.26 (+18.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About BGNE
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblast...
Financial Performance
In 2020, BeiGene's revenue was $308.87 million, a decrease of -27.87% compared to the previous year's $428.21 million. Losses were -$1.60 billion, 68.3% more than in 2019.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 424.26, which is an increase of 18.37% from the latest price.
News
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines...
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JN...
BeiGene Stock Rises 46% In A Month But Will The Rally Continue?
The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46% over the last twenty-one trading days, while it...
BeiGene Announces Inclusion in FTSE Russell Indices
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announced inclusion in several FTSE Russell indices.
Why BeiGene Shares Are Rising
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenström's macroglob...
Why BeiGene's Shares Jumped on Friday
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström's Ma...
BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the Eur...
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
3 Top Chinese Stocks to Watch in September
There are plenty of risks, but the rewards could be great.
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-ba...
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell C...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable med...
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...
Why BeiGene Stock Is Soaring This Week
The company won another FDA approval for blood cancer drug Brukinsa.
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion
The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.
BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication
The FDA has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM). Brukinsa WM approval is the second therapy approved...
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE--U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia
Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era
Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyng...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...
BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Wal...
BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, a...
BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China
The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) Qarziba (dinutuximab beta) in high-risk neuroblastoma patients....
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuro...
CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Admini...